2019年冠状病毒病(COVID-19)
纳米技术
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
大流行
2019-20冠状病毒爆发
药物输送
风险分析(工程)
重症监护医学
生化工程
材料科学
传染病(医学专业)
爆发
病毒学
医学
工程类
疾病
病理
作者
Inés Álvarez‐Miguel,Beatrice Fodor,Guillermo G. López,Catalina Biglione,Erik Svensson Grape,A. Ken Inge,Tania Hidalgo,Patricia Horcajada
标识
DOI:10.1021/acsami.4c06174
摘要
The SARS-CoV-2 (COVID-19) pandemic outbreak led to enormous social and economic repercussions worldwide, felt even to this date, making the design of new therapies to combat fast-spreading viruses an imperative task. In the face of this, diverse cutting-edge nanotechnologies have risen as promising tools to treat infectious diseases such as COVID-19, as well as challenging illnesses such as cancer and diabetes. Aside from these applications, nanoscale metal-organic frameworks (nanoMOFs) have attracted much attention as novel efficient drug delivery systems for diverse pathologies. However, their potential as anti-COVID-19 therapeutic agents has not been investigated. Herein, we propose a pioneering anti-COVID MOF approach by studying their potential as safe and intrinsically antiviral agents through screening various nanoMOF. The iron(III)-trimesate MIL-100 showed a noteworthy antiviral effect against SARS-CoV-2 at the micromolar range, ensuring a high biocompatibility profile (90% of viability) in a real infected human cellular scenario. This research effectively paves the way toward novel antiviral therapies based on nanoMOFs, not only against SARS-CoV-2 but also against other challenging infectious and/or pulmonary diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI